Safety and Tolerability of Long-Term Administration of Hydromorphone HCI CR (Controlled Release)
Status:
Completed
Trial end date:
2000-06-01
Target enrollment:
Participant gender:
Summary
The purpose of study was to characterize the safety and tolerability of long-term repeated
dosing of OROS hydromorphone controlled release tablets (8,16,32, and 64 mg) in patients with
chronic cancer pain or chronic non-malignant pain.